Skip to main content
EJNMMI Research

Table 1 Therapy protocol: classification of therapy groups and specification of administration of the BN analogues

From: PEGylation, increasing specific activity and multiple dosing as strategies to improve the risk-benefit profile of targeted radionuclide therapy with 177Lu-DOTA-bombesin analogues

Therapy groups

BN analogues

Dose and peptide amount

Injection time

Mice with PC-3 tumour xenografts

A

PBS

2 × 100 μl

Days 0 and 14

B

DOTA-PEG5k-Lys-BN

2 × 3.0 nmol

Days 0 and 14

C

177Lu-DOTA-PEG5k-Lys-BN

2 × 20 MBq/3.0 nmol each

Days 0 and 14

D

177Lu-DOTA-PEG5k-Lys-BN

2 × 20 MBq/0.3 nmol each

Days 0 and 14

E

177Lu-DOTA-PEG5k-Lys-BN

2 × 20 MBq/0.3 nmol each

Days 0 and 7

F

177Lu-DOTA-Lys-BN

2 × 20 MBq/0.3 nmol each

Days 0 and 14

Mice without PC-3 tumour xenografts

G

PBS

2 × 100 μl

Days 0 and 14

 

H

177Lu-DOTA-PEG5k-Lys-BN

2 × 20 MBq/0.3 nmol each

Days 0 and 14

 

I

177Lu-DOTA-PEG5k-Lys-BN

2 × 20 MBq/3.0 nmol each

Days 0 and 14

Back to article page